Application of secreted neurotoxin SN in preparation of medicine for treating idiopathic hypogonadotrophin gonadotrophy hypofunction

By discovering the function of secreted neuron SN regulates GnRH neurons, it solves the challenges of early diagnosis and treatment of idiopathic hypogonadism, provides new diagnostic targets and treatment options, and improves diagnostic accuracy and therapeutic effects.

CN119055745APending Publication Date: 2024-12-03INST OF AQUATIC LIFE ACAD SINICA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411142698.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There are challenges in the early diagnosis and treatment of idiopathic hypogonadism hypogonadism, existing treatment options may lead to non-targeted effects, and the causes of GnRH neuron developmental deficits in about 50% of cases are unknown.

Method used

It was found that the secreted neuron SN has the function of regulating the proliferation of GnRH neurons. The gene encoding SN can be used for early diagnosis of diseases and the development of SN as a new factor for therapeutic drugs.

Benefits of technology

Regulating GnRH neuron development through SN provides new treatment options, improving the accuracy of early diagnosis of the disease and targeting treatment, and reducing the non-targeted effect of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005001346590000011
    Figure HDA0005001346590000011
  • Figure HDA0005001346590000021
    Figure HDA0005001346590000021
  • Figure HDA0005001346590000031
    Figure HDA0005001346590000031
Patent Text Reader

Abstract

The invention belongs to the field of biological medicines, and discloses application of secreted neurotoxin SN in preparation of a medicine for treating idiopathic hypogonadotrophin gonadotrophy hypofunction. The method comprises the following steps: constructing a zebra fish model Tg (scg2a: mCherry / gnrh3: GFP) of a double-color fluorescence labeled Scg2a neuron and a GnRH3 neuron, and constructing a zebra fish model scg2a- / -of a double-color fluorescence labeled zebra fish model scg2a: mCherry / gnrh3: GFP of an scg2a mutation and a fluorescence labeled zebra fish model scg2a- / -of a GnRH3 neuron; the SN is a new factor for regulating growth of GnRH neurons, Tg (gnrh3: GFP), and is further combined with a mouse GnRH cell line for research, and the result shows that the SN has the function of regulating growth of the GnRH neurons and is a new factor for regulating growth of the GnRH neurons. The scg2 can be used as a new target for early diagnosis of the hypogonadotrophin gonadotrophin hypofunction, and the SN can be further developed into drugs for treating idiopathic hypogonadotrophin gonadotrophin hypofunction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to the application of secretoneuronin SN in the preparation of a drug for treating idiopathic hypogonadotropic hypogonadism, and the application of scg2 gene in the early diagnosis of hypogonadotropic hypogonadism. Background Art

[0002] Idiopathic Hypogonadotropic Hypogonadism (IHH) is a common endocrine disease characterized by partial or complete loss of puberty development. The global incidence rate is about 1-10 per 100,000 people, with a male to female ratio of 5:1. If the patient is accompanied by impaired sense of smell, it is called Kallmann syndrome (KS), also known as congenital infantile anosmia syndrome, which is the most common type of idiopathic hypogonadotropic hypogonadism.

[0003] Developmental defects of gonadotropin-releasing hormone (GnRH) neurons are one of the causes of idiopathic hypogonadotropic hypogonadism. The development of GnRH neurons is regulated by multiple factors, such as KAL1 gene (Sal enave et al. 2008), fibroblast growth factor receptor 1 gene (FGFRI) (Trarbach et al. 2010), fibroblast growth factor 8 gene (FGF8) (Falardeau et al. 2008), prokineticin 2 gene (PROK2) (Pitteloude et al. 2007), anti-Mullerian hormone gene (AMH) (Cimino et al. 2016; Malone et al. 2019) and nasal embryonic LHRH factor gene (NELF) (Kramer & Wray 2000). Mutations in genes that regulate the development of GnRH neurons are often the cause of hypogonadotropic hypogonadism (Silveira et al. 2010), and screening for related genes in patients usually finds the mutated gene. However, in about 50% of cases of hypogonadotropic hypogonadism, the cause of the defective development of GnRH neurons is still unknown (Malone et al. 2019).

[0004] Early diagnosis of hypogonadotropic hypogonadism has always been a difficult problem in clinical examinations. It is usually necessary to combine factors such as the development of sexual organs and secondary sexual characteristics, hormone levels and age to judge potential patients. However, most patients come for examination after they lack secondary sexual characteristics of puberty, and infants and young children cannot be identified early due to the lack of sexual characteristics development phenotype. Because it is a congenital genetic disease, IHH patients usually require lifelong treatment. The current treatment options are mainly based on the patient's age and whether there is a need for fertility, using estrogen androgen replacement, gonadotropin therapy and GnRH pulse therapy. However, regardless of the treatment option, the patient's total sperm count is usually lower than the normal threshold (Prior et al, 2018), and it may also have non-target effects, such as stimulating epiphyseal closure and affecting the patient's height; it may induce gonadotropin resistance in some patients, and may lead to polycystic ovarian changes or premature ovarian failure, etc.

[0005] Therefore, identifying genes that regulate the development of GnRH neurons will not only help screen potential IHH patients for related genes and provide a reference for early diagnosis of the disease, but also help deepen the understanding of IHH diseases caused by GnRH neuron developmental defects and provide guidance for the development of drugs to treat IHH diseases.

[0006] Fish GnRH3 is a hypophysial form of GnRH that induces the release of gonadotropin. The basic developmental patterns of fish GnRH3 neurons and mammalian GnRH1 neurons, including origin, migration, and projection, are consistent (Golan et al. 2021), suggesting that fish GnRH3 neurons not only play similar functions to mammalian GnRH1 neurons, but also that the two may have similar neuronal developmental regulatory mechanisms.

[0007] The Scg2 gene is mainly expressed in the dense core vesicles of neurons or endocrine cells. The protein encoded by it can form the neuroendocrine factor secretoneurin (SN) after proteolysis by prohormone convertase (Mitchell et al. 2020). SN is a neuropeptide containing 33-34 amino acids. It is very conserved in vertebrates such as mammals (including humans) and fish. Among them, zebrafish has two scg2 genes, scg2a and scg2b, and correspondingly has two secretoneurins, SNa and SNb (Trudeau et al. 2012). However, there is no report on whether SN has the function of regulating the development of GnRH neurons. Summary of the invention

[0008] The purpose of the present invention is to provide the use of secretoneuronin SN in the preparation of a drug for the treatment of idiopathic hypogonadotropic hypogonadism. The applicant has discovered for the first time that SN has the function of regulating the proliferation of GnRH neurons and is a new factor that regulates the development of GnRH neurons. The gene encoding the secretoneuronin SN can be used as a new target for the early diagnosis of hypogonadotropic hypogonadism.

[0009] In order to achieve the above object, the present invention adopts the following technical measures:

[0010] The applicant constructed a transgenic zebrafish Tg (scg2a:mCherry / gnrh3:GFP) with dual-color fluorescent labeling to show the positional relationship between Scg2a positive cells and GnRH3 neurons, and constructed a zebrafish scg2a with scg2a mutation and fluorescent labeling of GnRH3 neurons. - / - ; Tg(gnrh3:GFP), analyze the development of GnRH3 neurons after scg2a mutation. Use SNa peptide to incubate wild zebrafish and scg2a mutant zebrafish larvae, and analyze the regulation of SNa on the development of GnRH3 neurons in larvae. Use SNa peptide to inject zebrafish adult fish into the brain cavity, and analyze the regulation of SNa on the development of GnRH3 neurons in adult fish brains. Use mouse SN peptide to treat cultured mouse GnRH cell lines, and analyze the effect of SN on the development of mouse GnRH cells.

[0011] The protection scope of the present invention includes:

[0012] Use of secretoneurin SN in the preparation of a drug for treating idiopathic hypogonadotropic hypogonadism;

[0013] Use of a reagent for detecting a gene encoding a secretory neuron SN in the preparation of a drug for early diagnosis of hypogonadotropic hypogonadism;

[0014] In the above application, the secretory neuron SN is the secretory neuron SN of vertebrates;

[0015] In the above application, the secretory neuron SN is one of the active ingredients or the only active ingredient in the medicine.

[0016] In the above-mentioned applications, the dosage forms of the drugs include all dosage forms in the prior art, including but not limited to injections, tablets, capsules, oral liquid dosage forms, granules, etc.;

[0017] In the above application, preferably, the secretory neuron SN of the mammal in the vertebrate is shown as SEQ ID NO.1;

[0018] In the above application, preferably, the secretory neuron SNa of fish among the vertebrates is shown as SEQ ID NO.2.

[0019] Compared with the prior art, the present invention has the following advantages:

[0020] The applicant discovered for the first time that the secretory neuron SN has the function of regulating the development of GnRH neurons. To date, the cause of GnRH neuron development defects in about 50% of cases of hypogonadotropic hypogonadism is unknown. Currently, the techniques of estrogen androgen replacement, gonadotropin therapy and GnRH pulse therapy are used, which may have non-target effects and induce gonadotropin resistance in some patients. The present invention discovered that SN is a new factor that regulates the development of GnRH neurons. SN may be further developed into a drug for the preparation of idiopathic hypogonadotropic hypogonadism, and the gene encoding SN can be used as a new target for the early diagnosis of idiopathic hypogonadotropic hypogonadism, which has important application potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The distribution of Scg2a and GnRH3 neurons in the brain of Tg(scg2a:mCherry / gnrh3:GFP) juvenile zebrafish;

[0022] A: The distribution of neurons expressing the scg2a gene and GnRH3 neurons in 24hpf-96hpf zebrafish;

[0023] B is the statistical data of the percentage of GnRH3 cells expressing scg2a in the total number of GnRH3 neurons in Figure A.

[0024] Figure 2 The distribution of Scg2a and GnRH3 neurons in the brain of adult Tg(scg2a:mCherry / gnrh3:GFP) zebrafish;

[0025] AD: Confocal imaging of the whole brain of 3-month-old adult Tg(scg2a:mCherry / gnrh3:GFP) zebrafish, including: olfactory bulb A, telencephalon B, pituitary gland C, and hypothalamus D;

[0026] The image on the right of Figure D shows an enlarged view of the boxed area in the left image. The white arrows indicate that the scg2a gene and the gnrh3 gene are co-expressed in the same cell body or fiber.

[0027] Figure 3 The effect of zebrafish scg2a gene mutation on the number of GnRH3 neurons;

[0028] Among them: Tg1 and Tg2 represent Tg(gnrh3:GFP) and scg2a, respectively.- / - ;Tg(gnrh3:GFP) fish;

[0029] A: Confocal imaging of GnRH3 neurons in Tg1 and Tg2 larvae at 96 hpf;

[0030] B: Counting analysis found that the number of GnRH3 neurons in Tg2 was significantly lower than that in Tg1;

[0031] C: Confocal images of GnRH3 neurons in adult Tg1 and Tg2 fish;

[0032] D: Statistical analysis found that the fluorescence area of ​​GnRH3 neurons in the brain of Tg2 zebrafish was significantly lower than that of Tg1;

[0033] All data are presented as mean ± SEM (n = number of zebrafish analyzed), and statistical significance was assessed using a two-tailed Student's t-test.

[0034] Figure 4 The effect of zebrafish SNa peptide on the number of GnRH3 neurons in juvenile fish;

[0035] Among them: Tg1 and Tg2 represent Tg(gnrh3:GFP) and scg2a, respectively. - / - ; Tg(gnrh3:GFP) fish

[0036] A: Confocal imaging of the number of GnRH3 neurons in Tg1 and Tg2 zebrafish embryos incubated with SNa peptide until 36 hpf and 96 hpf, a white arrow represents a GnRH3 neuron;

[0037] Figure B shows the changes in the number of GnRH3 neurons after SNa incubation in Tg1 and Tg2 embryos at 36 hpf, and Figure C shows the changes in the number of GnRH3 neurons after SNa incubation in Tg1 and Tg2 embryos at 96 hpf; all data are expressed as mean ± SEM, and statistical significance was evaluated using a two-tailed Student t test.

[0038] Figure 5 The effect of zebrafish SNa peptide on the number of GnRH3 neurons in adult fish;

[0039] A: Confocal microscopy images of GnRH3 neurons in the brain tissue of adult fish at 10, 15, 20 and 30 days after PBS control and SNa polypeptide intracerebral injection;

[0040] B: Image J software was used to calculate the area of ​​GnRH3 neurons in each group in Figure A. All data are expressed as mean ± SEM, and the statistical significance was evaluated using a two-tailed Student's t test.

[0041] Figure 6The effect of SN on the number of GnRH neurons and gnrh1 expression in the mouse GT1-7 cell line;

[0042] A: Microscope photography of the number of GnRH neurons after treatment with different concentrations of mouse SN peptide;

[0043] B: Flow cytometry was used to count and calculate the number of GnRH neurons in each treatment group:

[0044] C: qPCR analysis of gnrh1 mRNA levels in GnRH cells after different treatments. Unpaired two-tailed Student's T test was used to compare the treatment groups, and the data shown are mean ± SEM.

[0045] The scale bars in all the above figures are 50 μm. DETAILED DESCRIPTION

[0046] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art; the reagents or materials described, unless otherwise specified, are all from commercial channels.

[0047] Embodiment 1:

[0048] The discovery that the zebrafish scg2a gene is associated with the development of GnRH3 neurons:

[0049] 1) Construction of dual-color fluorescent labeled transgenic zebrafish Tg (scg2a:mCherry / gnrh3:GFP)

[0050] Using zebrafish genomic DNA as a template, PCR amplification was performed with KOD enzyme to clone a zebrafish scg2a promoter fragment of 4074 bp in size. The primers for amplifying the scg2a promoter fragment were designed on the NCBI website (https: / / www.ncbi.nlm.nih.gov / tools / primer-blast / index.cgi?LINK_LOC=BlastHome):

[0051] F: 5'-TAGAGATTCTTGTTTAAGCTTGTGTTCATTTTAATTCGACA-3';

[0052] R: 5'-CACCATGGTGGCGGCGAATTCGAGCATCTCTGCGCTGGG-3';

[0053] The PCR amplification system was: 50 μL reaction system, 2 μL template, 5 μL KOD Buffer, 3 μL MgSO4, 3 μL dNTP, 1 μL primers, 1 μL KOD-Plus-Neo DNA polymerase; PCR amplification reaction conditions were: 94°C, 2 min; (98°C, 10 s; 60°C, 30 s; 68°C, 1-2 min; 35 cycles); 68°C, 7 min. Agarose gel electrophoresis was performed, and the target fragment was purified and recovered after gel cutting.

[0054] The Tol2-kdrl:mCherry plasmid (Tao et al, 2018) was double-digested with EcoRI and HindIII restriction endonucleases, the kdrl promoter was removed, and the vector fragment was recovered. Then, the homologous recombination was performed with the scg2a promoter fragment purified and recovered above to obtain the Tol2-scg2a:mCherry recombinant plasmid. The restriction digestion system is: Tol2-kdrl:mCherry plasmid 20μL (1000ng), 10×Buffer 10μL, EcoRI and HindIII restriction endonucleases 2μL each, and water was added to 100μL. The homologous recombination system is as follows: 2×Basic Assembly Mix 5μL, linearized Tol2-mCherry plasmid 1μL, scg2a promoter fragment 2μL, ddH2O 2μL. After mixing, react at 50℃ for 15min.

[0055] The homologous recombination product was added to the competent cells, placed on ice for 30 minutes, and immediately placed on ice for 2 minutes after heat shock at 42°C for 90 seconds. Then 700 μL of LB medium was added, shaken and cultured at 37°C for 30 minutes, and then spread on the medium containing antibiotics AMP+ and cultured at 37°C overnight. The next day, a single clone was picked as a template for bacterial liquid PCR verification and sequenced to obtain the recombinant plasmid Tol2-scg2a:mCherry.

[0056] The Tol2-scg2a:mCherry plasmid was microinjected into zebrafish fertilized eggs together with Tol2 transposase mRNA, and zebrafish that specifically expressed fluorescence were selected as P0 generation and raised to sexual maturity. The family establishment process was carried out according to the previous method of this laboratory (Guan et al. 2011). The mature P0 generation fish were cross-bred with wild zebrafish to obtain the F1 generation, and the F1 generation fluorescent fish were selected. The F1 generation fish were cross-bred with wild zebrafish to obtain the F2 generation. The positive F2 generation zebrafish were self-crossed to obtain the F3 generation of stable transgenic zebrafish family Tg (scg2a:mCherry). It was further hybridized with the constructed zebrafish with green fluorescence labeled GnRH3 neurons (Song et al, 2015) to obtain the dual-color fluorescent labeled zebrafish Tg (scg2a:mCherry / gnrh3:GFP). The positional relationship between Scg2a cells and GnRH3 neurons was observed using the Tg(scg2a:mCherry / gnrh3:GFP) zebrafish model. We observed 24hpf-96hpf fish and found that scg2a co-expression ( Figure 1 (A) (white arrows indicate the co-localization of Scg2a and GnRH3 neurons), and as development progresses, the proportion of GnRH3 neurons expressing the scg2a gene gradually increases from 10% to 40% ( Figure 1 In the brain of 3-month-old adult fish, many cells in the olfactory bulb (OB) expressed both scg2a and gnrh3 genes ( Figure 2 In the telencephalon (Tel), some Scg2a-expressing cells co-localize with GnRH3 neuron cell bodies in the ventral telencephalic nucleus (Vv) and the preoptic nucleus (PPa) ( Figure 2 In the pituitary (Pit), the distribution of scg2a and gnrh3 signals is almost the same. Both of them are projected from the neurohypophysis (N) to the ventrolateral part of the adenohypophysis (PPD) and the anterior lateral part of the adenohypophysis (RPD). In the N and PPD, the cell fibers of the two overlap and co-localize extensively ( Figure 2 C). Both scg2a signals and GnRH3 neurons are abundantly expressed in the hypothalamus (Hyp), where GnRH3 neuron cell bodies and fibers migrate along the outer edges of both sides of the ventral hypothalamus to the caudal periventricular hypothalamus, and some scg2a signals and GnRH3 neurons are co-localized in the ventral (Hv) and caudal (Hc) periventricular hypothalamus ( Figure 2 Middle D). The close positional relationship between Scg2a cells and GnRH3 neurons suggests that scg2a may have a regulatory effect on GnRH3 neurons.

[0057] 2) Construction of zebrafish scg2a mutant and fluorescently labeled GnRH3 neurons - / - ;Tg(gnrh3:GFP)

[0058] The zebrafish with scg2a mutation (Tao et al, 2018) and zebrafish Tg(gnrh3:GFP) (Song et al, 2015) with green fluorescence labeled GnRH3 neurons (hereinafter referred to as Tg1) were hybridized to obtain zebrafish scg2a with scg2a mutation and green fluorescence labeled GnRH3 neurons. - / - ; Tg(gnrh3:GFP) (the present invention or simply referred to as Tg2).

[0059] Confocal microscopy was used to compare the Tg1 and Tg2 at 96 hpf ( Figure 3 Middle A) and 3-month-old adult fish ( Figure 3 The GnRH3 neurons in C). It was found that the number of GnRH3 neurons in scg2a mutant larvae was significantly decreased compared with the control group ( Figure 3 Because there are too many GnRH3 neurons in adult fish, the area of ​​neurons was calculated using image J software instead. The results showed that the scg2a mutation caused a significant decrease in the area of ​​GnRH3 fluorescent cells in the brain of adult fish ( Figure 3 (D) Therefore, scg2a mutations affect the development of GnRH3 neurons.

[0060] Therefore, by detecting the expression of the scg2a gene in fish and comparing it with the expression of the scg2a gene in normal organisms, early diagnosis of idiopathic hypogonadotropic hypogonadism can be achieved. Since the scg2a gene is highly conserved in vertebrates, early diagnosis of idiopathic hypogonadotropic hypogonadism can be achieved by detecting the expression of scg2a gene homologous genes in vertebrates.

[0061] In the zebrafish of the present invention, the fluorescent quantitative primers designed by conventional methods: F: 5'-CAGGACGTACGGGTTATGCT-3'; R: 5'-GCGTTGGTCTTTGGTTTTGT-3' can be used to quantitatively detect the expression of the scg2a gene in zebrafish. For other vertebrates, the fluorescent quantitative primers designed by conventional methods in the art can also be used to perform the same detection.

[0062] Embodiment 2:

[0063] Regulation of SNa polypeptide on the development of GnRH3 neurons in zebrafish larvae

[0064] The protein encoded by the scg2a gene can be hydrolyzed by prohormone convertase to form secretoneurin A (SNa). We used the synthetic zebrafish SNa polypeptide (sequence: TNENEEQYTPQKLATLQSVFEEL SGIASSKTNT (Sangon Biotech 98.704% purity)) at a concentration of 100nM to incubate Tg1 and Tg2 embryos from 5hpf to 36hpf and 96hpf, and used confocal microscopy to image the number of GnRH3 neurons ( Figure 4 The results showed that at 36 hpf, incubation with SNa peptide could rescue the reduction in the number of GnRH3 neurons after scg2a mutation and restore it to normal levels; it could also significantly increase the number of GnRH3 neurons in wild fish ( Figure 4 At 96 hpf, it can be seen that after incubation with SNa peptide, the number of GnRH3 neurons in both scg2a mutant and wild-type zebrafish increased significantly ( Figure 4 The above results indicate that SNa polypeptide has a positive effect on the development of GnRH3 neurons in young fish.

[0065] Embodiment 3:

[0066] Regulation of SNa polypeptide on the development of GnRH3 neurons in adult zebrafish

[0067] SNa peptide was continuously injected into the brain cavity of 3-month-old adult Tg1 zebrafish every other day. The injection method is referred to the literature (Kizil C, Iltzsche A, Kaslin J, et al. Micromanipulation of Gene Expression in the Adult Zebrafish Brain Using Cerebroventricular Microinjection of Morpholino Oligonucleotide s [J]. Journal of Visualized Experiments Jove, 2013 (75). DOI: 10.3791 / 50415.). First, prepare a glass capillary tube and use a needle puller to obtain the following parameters: heating cycle value: 463, pulling cycle value: 230, speed: 1.5 seconds, time: 75 milliseconds. Prepare a 1 mg / mL concentration of SNa peptide solution with PBS solution, add 9 μl SNa solution and 1 μl fluorescent tracking dye (such as CellTracker Red CMTPX, Invitrogen), and load the mixed solution into the glass capillary tube. Before injection, turn on the pressure source, adjust the pressure setting to 50 psi or 3.5 bar, and adjust the microinjector settings as follows: holding pressure to 20 psi, injection pressure to 10 psi, cycle value to 2.5, and gating range to 100 ms.

[0068] The experimental fish was taken out of the fish tank and placed in a plastic tank with sufficient water, and 40 mg / L of MS-222 anesthetic was prepared in a small plastic box. When the intracerebral injection was started, the adult zebrafish was placed in a small tank containing anesthetic until the fish floated. The fish was taken out and wrapped with moist gauze and the head was exposed under a microscope. After cutting the optic tectum skull plate with a 30-gauge syringe needle, no more than 0.5-1 μl of the SNa polypeptide and tracking dye mixed solution was injected into the ventricular fluid from the incision toward the telencephalon using the tip of a glass capillary, avoiding damage to the brain tissue.

[0069] Adult fish in the control group were injected with a mixture of PBS and tracking dye.

[0070] After intracerebrospinal injection, the fish were placed in clean water to recover. We killed the adult fish in the experimental and control groups 10, 15, 20, and 30 days after injection, and removed the whole brains. The number of GnRH3 neurons was recorded using a confocal microscope ( Figure 5 The study found that starting from the 15th day after intracerebral injection of SNa peptide, the number of GnRH3 neurons in the adult fish brain increased significantly compared with the control zebrafish ( Figure 5 (middle B).

[0071] Therefore, SNa may serve as a potential new target for the diagnosis and treatment of idiopathic hypogonadotropic hypogonadism.

[0072] Embodiment 5:

[0073] Regulatory Effects of SN Peptide on Cultured Mouse GnRH Cell Line

[0074] Mouse GnRH hypothalamic cell line GT1-7 cells were cultured in DMEM (Gibco C11995500BT) containing 4.5 g / L glucose, L-glutamine, 110 mg / L sodium pyruvate, 10% fetal bovine serum, and 1% penicillin / streptomycin. GT1-7 cells were cultured in a cell culture incubator at 37°C and 5% CO2. When the cell growth reached about 70-80%, the cells were cultured in a 37°C, 5% CO2 incubator.

[0075] Afterwards, GT1-7 cells were cultured in fresh medium containing 0 nM, 100 nM, 200 nM and 400 nM mouse SN polypeptide for another 12 h.

[0076] The mouse SN polypeptide was artificially synthesized (sequence: TNEIVEEQYTPQSLATLESVFQELGKLTGPS NQ (Sangon Biotech 99.073% purity)).

[0077] After the culture is completed, remove the original culture medium and add PBS to rinse the cells once, then remove the PBS. Then add a small amount of trypsin to the culture dish for digestion, gently shake the culture medium so that the cells are no longer attached to the wall, and then add at least one volume of DMEM to terminate the digestion. Centrifuge at 3000rpm for 5 minutes and discard the supernatant.

[0078] The cells were resuspended in PBS for microscopic imaging ( Figure 6 A) and flow cytometry (CytoFlex S, Beckman), it was found that in the mouse GT1-7 cell line, with the increase of 100nM, 200nM and 400nM SN peptide concentrations, the number of GnRH cells also gradually increased, which was significantly higher than that of the control group ( Figure 6B). The remaining cell samples were used to extract total RNA. The cell suspension was centrifuged at 12000rpm for 1min, and 400μL TRIzol was added after the supernatant was discarded and stored in a -80℃ refrigerator. The relevant reagents, pipette tips, centrifuge tubes, and centrifuges in the RNA extraction process were all nuclease-free, and the extraction process was performed on a nuclease-free RNA operating table. When extracting total RNA, the sample was thawed at room temperature, ground with an electric homogenizer, and allowed to stand for 5 minutes. Centrifuge at 12000rpm and 4℃ for 10min. Transfer the supernatant to a new RNase-free 1.5ml EP tube. Add 160μL chloroform, shake vigorously for 15s to mix, and let it stand at room temperature for 10 minutes. Centrifuge at 12000rpm and 4℃ for 10min. Carefully pipette 250μL of the upper aqueous phase into a clean 1.5mL RNase-free EP tube, add 250μL isopropanol, mix thoroughly, and let it stand at room temperature for 10 minutes. 12000rpm, 4℃ centrifuge for 10min, discard the supernatant, the white precipitate at the bottom of the tube is the total RNA. Wash the precipitate with 1mL of pre-cooled 75% ethanol. 7500rpm, 4℃ centrifuge for 5min, discard the supernatant, and dry naturally. Add an appropriate amount of RNase-free water to dissolve the precipitate according to the amount of precipitate. Take 1μL of sample to detect the concentration and purity with a spectrophotometer, and take another 1μL sample to detect the quality of RNA by agarose gel electrophoresis. Next, use the reverse transcription kit (TOYO BO, Japan) to synthesize cDNA. The main steps are as follows: Take 1μg of total RNA, add an appropriate amount of RNase-free H 2O to 6μL, heat at 65℃ for 5min, and then ice bath for 2min. Add 2μL 4×DN Master mix (with gRNA remover added: 440μL 4×DN Master mix+8.8μL gRNA remover), mix well, and digest genomic DNA at 37℃ for 5min. Add 2μL 5×RT Master MixⅡ, mix well, and synthesize cDNA in a PCR instrument under the following conditions: 37℃, 15min; 50℃, 5min; 98℃, 5min; 4℃+∞; the final product is stored at -20℃. The cDNA sample was diluted 5 times and used as a template. β-actin was used as an internal reference gene to detect the expression of the gnrh1 gene. The primer sequences were as follows: β-actin-F: 5'-CCATCATGAAGTGTGACGTTG-3'; β-actin-R: 5'-ACAGAGTAC TTGCGCTCAGGA-3'; gnrh1-F: 5'-GCATTCTACTGCTGACTGTGTGTT-3'; gnrh1-R: 5'-GTTCTGCCATTTGATCCACCT-3'. The real-time PCR reaction system was as follows: 2×SYBR Green Mix 10μL, 0.5μL of upstream and downstream primers, 2μL of cDNA template, dd H 2 O 7μL. The operating program was as follows: 95℃, 3min; 40 cycles were performed as follows: 95℃, 15s; 60℃, 15s; 72℃, 15s. Three technical replicates were performed for each experiment. The expression level of the target gene was normalized to the expression level of β-actin. Data analysis was performed using 2 - △△ct Quantitative PCR showed that SN peptide treatment could increase the expression level of gnrh1 in GT1-7 cells, with a significant increase at 100nM and 200nM concentrations ( Figure 6 Middle C).

[0079] The above results indicate that SN can directly act on GnRH neurons and the function of SN in regulating the development of GnRH neurons is conserved in zebrafish and mice.

[0080] In summary, this study not only provides new scientific data for understanding the development of the GnRH nervous system, but also is expected to bring new inspiration for the development and treatment of drugs for hypogonadotropic hypogonadism.

Claims

1. Application of secretoneurin SN in the preparation of drugs for the treatment of idiopathic hypogonadotropic hypogonadism.

2. Use of a reagent for detecting a gene encoding a secretory neuron SN in the preparation of a drug for early diagnosis of hypogonadotropic hypogonadism.

3. The use according to claim 1 or 2, wherein the secretory neuron SN is a secretory neuron SN of a vertebrate.

4. According to claim 1 or the reference I described, the secretory neuron SN is one of the active ingredients or the only active ingredient in the drug.

5. According to claim 1 or the reference I described, the dosage form of the drug includes injection, tablet, capsule, oral liquid dosage form, granule.

6. The use according to claim 3, wherein the secretory neurotrophin SN of the mammal among the vertebrates is shown as SEQ ID NO.

1.

7. The use according to claim 3, wherein the secretory neuron SNa of fish among the vertebrates is shown as SEQ ID NO.2.